Novartis shareholders approve all the resolutions proposed by the Board of Directors at the Annual General Meeting of 2025 | 07.03.25

• Approved Shareholders 28^th Increased consecutive dividends to Chf 3.50 (+6.1 %) per share by 2024, which represents a 3.5 %yield ¹
• The shareholders elected Giovanni Caforio as the new member and president of the Board of Directors, as well as Elizabeth McNally as the new member of the Board of Directors. Joerg Reinhardt, Charles L. Sawyers and William T. Winters did not defend re -election
• The shareholders approved all the other proposals by the Board of Directors, including the reduction of the share capital, the 2024 report on non -financial matters and the compensation report of 2024, as well as the future compensation of the Board and Executive Committee in separated binding votes

Basilea, March 7, 2025 – Novartis shareholders agreed today the recommendations of the Board of Directors for all the resolutions proposed in the Company General Board (AGM). A total of 1,693 shareholders were present at the meeting held in Basel, which represents approximately 57.42% of the actions issued by Novartis.

With an increase in dividends of 6.1% to Chf 3.50 per share, the shareholders approved the 28^th consecutive increase, resulting in a dividend yield of 3.5%¹. The payment of the 2024 dividend will be made as of March 13, 2025.

Election of the new president of the Board and a new member of the Board
The shareholders have chosen Giovanni Caforio as the new member of the Board of Directors and president of the Board.

In addition, the shareholders chose Elizabeth McNally as the new member of the Board of Directors. Joerg Reinhardt, Charles L. Sawyers and William T. Winters did not defend re -election. All other members of the Board of Directors have been re -elected. All elections and reelections belong to a term that lasts until the end of the next AGM.

The shareholders also re -elected all the current members of the Compensation Committee and chose John D. Young as a new member of the Compensation Committee, each for a period that lasts until the end of the next AGM. With its re -election, Simon Moroney remains president of the in -line committee with the appointment of the Board of Directors.

The professional history of the members of the Board of Directors can be found in: www.novartis.com/about/board-director.

Share capital reduction
The shareholders also approved the proposal of the Board of Directors to cancel 77 508 630 shares and reduce the share capital consequently by Chf 37 979 228.70 (of CHF 1 073 065 943.53 A CHF 1 035 086 714.83).

Other shares of shares
To allow the complete execution of the repurchase of shares already announced of up to 15 billion CHF and possible repurchases of additional shares, the shareholders approved the proposal of the Board of Directors to authorize the Board of Directors to recommend the shares as considered appropriate from time to time in time to the time up to 10 billion CHF of the AGM 202 to the AGM 2028. This adds to the remaining authorization of 3,500 million Chf² of the AGM of 2022 and 2023.

Compensation for the Board of Directors and the Executive Committee
In two separate binding votes, the shareholders approved the total total amount of compensation for the Board of Directors, which covers the period from the AGM 2025 to the AGM 2026, and the total maximum amount of compensation for the Executive Committee for the Financial Year 2025. The shareholders further supported the 2024 compensation report in an advice vote.

Resolution
To obtain a detailed list of all resolutions in the AGM 2025, visit:

Discharge of responsibility
This press release contains prospective statements in the sense of the Law on the Reform of Private Securities Litigation of the United States of 1995. Future vision statements can generally be identified by words as “potential”, “can”, “plan”, “” can “,” could “”, “,” wait “,” anticipate “,” look forward “,” believe, “committed”, “research” “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “,”, “. Implicit discussions on possible marketing approvals, new indications or labeling for investigation or approved products described in this press release, or on possible future income of these products, should not establish undue confidence in these statements to vision The incorrect real results may vary materially from those established in the prospective statements. It cannot be guaranteed that the investigation or approved products described in this press release will be presented or approved for sale or for any additional indication or labeling in any market, or at a particular time. Nor can there be any guarantee that these products will have commercial success in the future. In particular, our expectations with respect to such products could be affected by, among other things, the uncertainties inherent in research and development, including the results of clinical trials and the additional analysis of existing clinical data; regulatory actions or delays or government regulation in general; Global trends towards the containment of medical care costs, including government, payer and general public prices and reimbursement pressures and requirements for greater price transparency; our ability to obtain or maintain the protection of patented intellectual property; the particular prescription preferences of doctors and patients; General political, economic and commercial conditions, including effects and efforts to mitigate pandemic diseases; security, quality, data integrity or manufacturing problems; Potential data security or real data privacy violations, or interruptions of our information technology systems, and other risks and factors mentioned in the current Navartis AG file with the US stock and stock and values ​​commission Another way.

About Novartis
Novartis is an innovative drug company. Every day, we work to reinvent medicine to improve and extend the lives of people so that patients, health professionals and societies are entitled to serious diseases. Our medications reach almost 300 million people worldwide.

Reimagine Medicine With Us: Visit us in and connect with us in LinkedIn, Facebook, X/Twitter and Instagram.

References

1. Based on the closing price of Chf 99.47 of Novartis Six Swiss Exchange of Chf 99.47 on March 6, 2025
2. As of December 31, 2024

# # #